Inhibition of Toxoplasma gondii by 1,2,4-triazole-based compounds: marked improvement in selectivity relative to the standard therapy pyrimethamine and sulfadiazine

References

• Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000;30:1217–58.
   PubMed Web of Science ®Google Scholar
• Vaillant V, de Valk H, Baron E, et al. Foodborne infections in France. Foodborne Pathog Dis 2005;2:221–32.
   PubMed Web of Science ®Google Scholar
• Carradori S, Secci D, Bizzarri B, et al. Synthesis and biological evaluation of anti-Toxoplasma gondii activity of a novel scaffold of thiazolidinone derivatives. J Enzyme Inhib Med Chem 2017;32:746–58.
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 2012;25:264–96.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Schlüter D, Mänz M. Ocular toxoplasmosis: recent aspects of pathophysiology and clinical implications. Ophthalmic Res 2014;52:116–23.
   PubMed Web of Science ®Google Scholar
• Ferreira LB, Furtado JM, Charng J, et al. Prevalence of toxoplasmic retinochoroiditis in an australian adult population: a community-based study. Ophthalmol Retina 2022. Article in press.
   Google Scholar
• Fabiani S, Pinto B, Bonuccelli U, Bruschi F. Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases. J Neurol Sci 2015;351:3–8.
   PubMed Web of Science ®Google Scholar
• Ngoungou EB, Bhalla D, Nzoghe A, et al. Toxoplasmosis and epilepsy – systematic review and meta analysis. PLoS Negl Trop Dis 2015;9:e0003525.
   PubMed Web of Science ®Google Scholar
• Ngô HM, Zhou Y, Lorenzi H, et al. Toxoplasma modulates signature pathways of human epilepsy, neurodegeneration & cancer. Sci Rep 2017;7:11496.
   PubMed Web of Science ®Google Scholar
• Furtado JM, Lansingh VC, Carter MJ, Milanese MF, et al. Causes of blindness and visual impairment in Latin America. Surv Ophthalmol 2012;57:149–77.
   PubMed Web of Science ®Google Scholar
• Wang ZD, Liu HH, Ma ZX, et al. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-Analysis. Front Microbiol 2017;8:389.
   PubMed Web of Science ®Google Scholar
• Da Cunha S, Ferreira E, Ramos I, et al. Cerebral toxoplasmosis after renal transplantation. Case report and review. Acta Med Port 1994;7:S61–S66.
   PubMedGoogle Scholar
• Pott H, Jr, Castelo A. Isolated cerebellar toxoplasmosis as a complication of HIV infection. Int J STD AIDS 2013;24:70–2.
   PubMed Web of Science ®Google Scholar
• Agrawal SR, Singh V, Ingale S, Jain AP. Toxoplasmosis of spinal cord in acquired immunodeficiency syndrome patient presenting as paraparesis: a rare entity. J Glob Infect Dis 2014;6:178–81.
   PubMedGoogle Scholar
• Lu N, Liu C, Wang J, et al. Toxoplasmosis complicating lung cancer: a case report. Int Med Case Rep J 2015;8:37–40.
   PubMed Web of Science ®Google Scholar
• Jingjing W, Xiumei L, Nanqu H, et al. Misdiagnosis of HIV with toxoplasmosis encephalopathy with progressive memory loss as the initial symptom: a case report. Front Neurol 2022;13:809811.
   PubMed Web of Science ®Google Scholar
• Ayoade F, Joel Chandranesan AS, HIV-1 associated toxoplasmosis. [Updated 2021 Sep 18]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441877/.
   Google Scholar
• Vidal JE. HIV-related cerebral toxoplasmosis revisited: current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care 2019;18:232595821986731–20.
   Google Scholar
• Bollani L, Auriti C, Achille C, et al. Congenital toxoplasmosis: the state of the art. Front Pediatr 2022;10:894573.
   PubMed Web of Science ®Google Scholar
• Bissati KE, Levigne P, Lykins J, et al. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerg Microb Infect 2018;7:1–14.
   PubMed Web of Science ®Google Scholar
• Tomasoni LR, Messina G, Genco F, et al. Risk of congenital toxoplasmosis in women with low or indeterminate anti-Toxoplasma IgG avidity index in the first trimester of pregnancy: an observational retrospective study. Clin Microbiol Infect 2019;25:761.e9–761–e13.
   Web of Science ®Google Scholar
• Pinheiro BV, de Lourdes Meirelles Noviello M, Cunha MM, et al. Pathological changes in acute experimental toxoplasmosis with Toxoplasma gondii strains obtained from human cases of congenital disease. Exp Parasitol 2015;156:87–94.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363:1965–76.
   PubMed Web of Science ®Google Scholar
• McLeod R, Lykins J, Gwendolyn Noble A, et al. Management of congenital toxoplasmosis. Curr Pediatr Rep 2014;2:166–94.
   Google Scholar
• Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004;113:1567–72.
   PubMed Web of Science ®Google Scholar
• Dunay IR, Gajurel K, Dhakal R, et al. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev 2018;31:e00057–17.
   PubMed Web of Science ®Google Scholar
• Hopper AT, Brockman A, Wise A, et al. Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. J Med Chem 2019;62:1562–76.
   PubMed Web of Science ®Google Scholar
• Anderson AC. Targeting DHFR in parasitic protozoa. Drug Discov Today 2005;10:121–8.
   PubMed Web of Science ®Google Scholar
• Alday PH, McConnell EV, Boitz Zarella JM, et al. Acridones are highly potent inhibitors of Toxoplasma gondii tachyzoites. ACS Infect Dis 2021;7:1877–84.
   PubMed Web of Science ®Google Scholar
• Rajapakse S, Chrishan Shivanthan M, Samaranayake N, et al. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health 2013;107:162–9.
   PubMed Web of Science ®Google Scholar
• Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1643–8.
   PubMed Web of Science ®Google Scholar
• Montazeri M, Daryani A, Ebrahimzadeh M, et al. Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis. Jundishapur J Microbiol 2015;8:e22572.
   PubMed Web of Science ®Google Scholar
• Montazeri M, Mehrzadi S, Sharif M, et al. Drug resistance in Toxoplasma gondii. Front Microbiol 2018;9:2587.
   PubMed Web of Science ®Google Scholar
• McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study. Clin Infect Dis 2006;42:1383–94.
   PubMed Web of Science ®Google Scholar
• Abdullahi SA, Unyah NZ, Nordin N, et al. Phytochemicals and potential therapeutic targets on Toxoplasma gondii parasite. Mini Rev Med Chem 2020;20:739–53.
   PubMed Web of Science ®Google Scholar
• Lai BS, Witola WH, El Bissati K, et al. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci USA 2012;109:14182–7.
   PubMed Web of Science ®Google Scholar
• Angel SO, Vanagas L, Ruiz DM, et al. Emerging therapeutic targets against Toxoplasma gondii: update on DNA repair response inhibitors and genotoxic drugs. Front Cell Infect Microbiol 2020;10:289.
   PubMed Web of Science ®Google Scholar
• Huang L, Liu B, Liu Z, et al. Gut microbiota exceeds cervical microbiota for early diagnosis of endometriosis. Front Cell Infect Microbiol 2021;11:788836.(a) McPhillie M, Zhou Y, Hickman MR, et al. Potent tetrahydroquinolone eliminates apicomplexan parasites. Front Cell Infect Microbiol 2020;10:203.
   PubMed Web of Science ®Google Scholar
• Paneth A, Węglińska L, Bekier A, et al. Discovery of potent and selective halogen-substituted imidazole-thiosemicarbazides for inhibition of Toxoplasma gondii growth in vitro via structure-based design. Molecules 2019;24:1618.
   PubMed Web of Science ®Google Scholar
• Paneth A, Węglińska L, Bekier A, et al. Systematic identification of thiosemicarbazides for inhibition of Toxoplasma gondii growth in vitro. Molecules 2019;24:614.
   PubMed Web of Science ®Google Scholar
• Siwek A, Wujec M, Dobosz M, Wawrzycka-Gorczyca I. Study of direction of cyclization of 1-azolil-4-aryl/alkyl-thiosemicarbazides. Heteroatom Chem 2010;21:521–5.
   Web of Science ®Google Scholar
• Almasirad A, Mousavi Z, Tajik M, et al. Synthesis, analgesic and anti-inflammatory activities of new methyl-imidazolyl-1,3,4-oxadiazoles and 1,2,4-triazoles. J Pharm Sci 2014;22:22.
   Web of Science ®Google Scholar
• Alday PH, Doggett JS. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther 2017;11:273–93.
   PubMed Web of Science ®Google Scholar
• Subauste CS, Montoya JG, Remington JS. AIDS-associated toxoplasmosis. Global HIV/AIDS medicine. Philadelphia (PA): Saunders/Elsevier; 2008:399–413.
   Google Scholar
• Ozturk R, Engin A, Ozaras R, et al. Hyperpigmentation due to pyrimethamine use. J Dermatol 2002;29:443–5.
   PubMed Web of Science ®Google Scholar
• Haverkos HW. Assessment of therapy for toxoplasma encephalitis. The TE study group. Am J Med 1987;82:907–14.
   PubMed Web of Science ®Google Scholar
• Becker K, Jablonowski H, Häussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) 1996;75:185–94.
   PubMed Web of Science ®Google Scholar
• Greene EM, Hagemann TM, Drug-induced hematologic disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L, eds. Pharmacotherapy: a pathophysiologic approach. New York (NY): McGraw Hill; 2017:10e. https://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=146079796 (accessed June 21, 2022).
   Google Scholar
• Lara FA, Kahn SA, da Fonseca AC, et al. On the fate of extracellular hemoglobin and heme in brain. J Cereb Blood Flow Metab 2009;29:1109–20.
   PubMed Web of Science ®Google Scholar
• Ostling O, Johanson KJ. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 1984;123:291–8.
   PubMed Web of Science ®Google Scholar
• Dzitko K, Paneth A, Plech T, et al. Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis. Antimicrob Agents Chemother 2014;58:7583–5.
   PubMed Web of Science ®Google Scholar
• Martins-Duarte ÉS, Lemgruber L, de Souza W, Vommaro RC. Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model. Exp Parasitol 2010;124:466–9.
   PubMed Web of Science ®Google Scholar
• Laliberté J, Carruthers VB. Host cell manipulation by the human pathogen Toxoplasma gondii. Cell Mol Life Sci 2008;65:1900–15.
   PubMed Web of Science ®Google Scholar
• Marino ND, Boothroyd JC. Toxoplasma growth in vitro is dependent on exogenous tyrosine and is independent of AAH2 even in tyrosine-limiting conditions. Exp Parasitol 2017;176:52–8.
   PubMed Web of Science ®Google Scholar
• Bekier A, Brzostek A, Paneth A, et al. 4-arylthiosemicarbazide derivatives as toxoplasmic aromatic amino acid hydroxylase inhibitors and anti-inflammatory agents. Int J Mol Sci 2022;23:3213.
   PubMed Web of Science ®Google Scholar
• Dellacasa-Lindberg I, Hitziger N, Barragan A. Localized recrudescence of Toxoplasma infections in the central nervous system of immunocompromised mice assessed by in vivo bioluminescence imaging. Microbes Infect 2007;9:1291–8.
   PubMed Web of Science ®Google Scholar
• Melzer TC, Cranston HJ, Weiss LM, Halonen SK. Host cell preference of Toxoplasma gondii cysts in murine brain: a confocal study. J Neuroparasitology 2010;1:1–6.
   Google Scholar
• Joynson DH, Wreghitt TJ, Toxoplasmosis: a comprehensive clinical guide. Cambridge: Cambridge University Press; 2001.
   Google Scholar
• Flegr J. Effects of toxoplasma on human behavior. Schizophr Bull 2007;33:757–60.
   PubMed Web of Science ®Google Scholar
• Kocazeybek B, Oner YA, Turksoy R, et al. Higher prevalence of toxoplasmosis in victims of traffic accidents suggest increased risk of traffic accident in Toxoplasma-infected inhabitants of Istanbul and its suburbs. Forensic Sci Int 2009;187:103–8.
   PubMed Web of Science ®Google Scholar
• Kar N, Misra B. Toxoplasma seropositivity and depression: a case report. BMC Psychiatry 2004;4:1.
   PubMed Web of Science ®Google Scholar
• Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis 2003;9:1375–80.
   PubMed Web of Science ®Google Scholar
• Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007;33:729–36.
   PubMed Web of Science ®Google Scholar
• Flegr J, Preiss M, Klose J, et al. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii Dopamine, a missing link between schizophrenia and toxoplasmosis? Biol Psychol 2003;63:253–68.
   PubMed Web of Science ®Google Scholar
• Webster JP, Lamberton PH, Donnelly CA, Torrey EF. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc Biol Sci 2006;273:1023–30.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3–14.
   PubMedGoogle Scholar
• Pardridge WM, Brain drug targeting: the future of brain drug development. Cambridge: Cambridge University Press; 2001.
   Google Scholar
• Galdeano C, Coquelle N, Cieslikiewicz-Bouet M, et al. Increasing polarity in tacrine and huprine derivatives: potent anticholinesterase agents for the treatment of Mmyasthenia gravis. Molecules 2018;23:634.
   PubMed Web of Science ®Google Scholar
• Hodge JM, Coghill AE, Kim Y, et al. Toxoplasma gondii infection and the risk of adult glioma in two prospective studies. Int J Cance 2021.
   Web of Science ®Google Scholar